National Cancer Institute - Crizotinib - Stage IB-IIIA Non-small Cell Lung Cancer

National Cancer Institute active clinical trial for non-small cell lung cancer 

Trial name: Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Status: Active
Age:
18 years and over
Gender:
Male or Female
Location:
1265 locations

Crizotinib is a cancer medication that interferes with the growth and spread of cancer cells in the body. Xalkori is used to treat non-small cell lung cancer. Crizotinib may also be used for purposes not listed in this medication guide.

Please find details on www.cancer.gov .

 

 

 

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.